Arlington, VA (PRWEB) May 13, 2014
The pharmaceutical Metformin was first used to treat metabolic disorders over 80 years ago. Since that time, it has become the world's most widely used anti diabetic drug. It has earned a sterling reputation as being effective and well tolerated, with very few adverse effects. The World Health Organisation has classified Metformin as one of only two anti-diabetic drugs on its list of Essential Medicines. Now, Metformin may be getting a new lease on life thanks to Resveratrol, a compound often associated with the red wine grape and the French Paradox.
In a peer reviewed study published today in the journal European Endocrinology, http://www.touchendocrinology.com/articles/resveratrol-management-diabetes-and-its-downstream-pathologies?page=0,1 it was reported that a compelling body of both human clinical evidence and in vitro data confirm that Resveratrol amplifies and extends the beneficial actions of Metformin, and that physicians treating Type 2 Diabetes Mellitus patients with Metformin should now consider augmenting their treatment protocol by adding Resveratrol as a safe and effective nutraceutical adjuvant. This natural phytoalexin, in doses of 500mg per day, was first shown in a widely reported human clinical trial undertaken at the Albert Einstein Medical College in 2005 to impede the evolution of pre diabetes, into Type 2 Diabetes Mellitus. A second clinical trial at the same university in 2012 concluded that Resveratrol “may possess relevant clinical effects on glucose metabolism and vascular function.”
Larger scale, placebo controlled, randomized human trials published in 2013 and 2014 have confirmed the preventative and therapeutic value of Resveratrol. In the most recent review of Resveratrol and Diabetes authored by researchers James Betz and Moola Nanjan, the compound was shown to significantly enhance the ability of Metformin to increase insulin sensitivity, lower blood glucose levels, and improve mitochondrial function. Furthermore Resveratrol's beneficial effects went beyond those of Metformin by lowering blood pressure, decreasing body weight, and attenuating both HDL and triglyceride cholesterol levels. Resveratrol in conjunction with Metformin was also shown to be effective in delaying or preventing the serious downstream pathologies that affect diabetic patients. The new review presents clinical and in vitro evidence of Resveratrol's ability to inhibit diabetic nephropathy, a potentially disabling kidney disease, improve cardiovascular health, and prevent diabetic retinopathy, a condition in which the small blood vessels of the eye rupture and cause vision loss, often leading to permanent blindness. Dr. David Sinclair, a Harvard University scientist, was chosen by Time Magazine recently as one of the 100 most influential persons for his discovery that Resveratrol activates a class of genes called Sirtuins.
James Betz, chief science officer for Biotivia Labs, and one of the paper's authors, commented, “The evidence of Resveratrol's effectiveness against the underlying causal modalities of diabetes and other metabolic disorders has been steadily accumulating over the past decade or more. The remarkably consistent human trial findings published during 2012, 2013 and 2014 have confirmed that the science behind Resveratrol translates into real world benefits to Diabetes patients. Biotivia will continue to support diabetes research at universities in the US, Europe, the Middle East and Asia. Resveratrol is one of an array of natural Sirtuin activators that have shown impressive effectiveness agains this disease. NAD+ is another such molecule, although the evidence behind this coenzyme is not as extensive.”
About Biotivia Labs
Biotivia is a nutraceutical research and manufacturing company that specializes in natural compounds which exhibit the potential to prevent and treat the chronic conditions associated with ageing and obesity. Their scientists and expert staff collaborate with major university medical schools and researchers worldwide. They also contribute proprietary formulations, including Resveratrol and NAD+ for use in human clinical trials investigating potential applications as chemo-preventatives against metabolic disorders, cardiovascular Disease, some cancers, and ageing.